Skip to content
DataLookout
Start free
Menu

NCT07109362

ERP-Based Research on the Modulation of Remimazolam on Working Memory and Brain Network Mechanisms in Glioma Patients

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 7 more changesShow less
    • Completed without a posted recruiting period
    • Final enrollment: 70 participants (planned 60)
    • Primary completion date changed from estimate of Jun 30, 2026 to Aug 30, 2026
    • Study completion date changed from estimate of Jul 30, 2026 to Sep 15, 2026
    • Start date changed from estimate of Aug 10, 2025 to Aug 8, 2025
    • Eligibility criteria expanded, about 17 words
    • Site contact updated
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

behavioral results, including d', reaction time and accuracy rate
Timeframe: All participants completed the working memory test one day before the surgery.
P3b event-related potential (ERP)
Timeframe: All participants completed the working memory test one day before the surgery, with simultaneous collection of 64-channel scalp electroencephalogram (EEG).

Arms and interventions

Healthy brain groupOther
Glioma brain groupOther

Drugs: mild sedation

Sites

1 site in 1 country

  • Beijing Tiantan HospitalBeijing, China